Neovascular age-related macular degeneration (AMD) is treated with anti-VEGF intravitreal injections, which can cause geographic atrophy, infection, and retinal fibrosis. To minimize these toxicities, we developed a nanoparticle delivery system for recombinant Flt23k intraceptor plasmid (RGD.Flt23k.NP) to suppress VEGF intracellularly within choroidal neovascular (CNV) lesions in a laser-induced CNV mouse model through intravenous administration. In the current study, we examined the efficacy and safety of RGD.Flt23k.NP in mice. The effect of various doses was determined using fluorescein angiography and optical coherence tomography to evaluate CNV leakage and volume. Efficacy was determined by the rate of inhibition of CNV volume at 2 weeks post-treatment. RGD.Flt23k.NP had peak efficacy at a dose range of 30-60 mg pFlt23k/mouse. Using the lower dose (30 mg pFlt23k/mouse), RGD.Flt23k.NP safety was determined both in single-dose groups and in repeat-dose (three times) groups by measuring body weight, organ weight, hemoglobin levels, complement C3 levels, and histological changes in vital organs. Neither toxicity nor inflammation from RGD.Flt23k.NP was detected. No side effect was detected on visual function. Thus, systemic RGD.Flt23k.NP may be an alternative to standard intravitreal anti-VEGF therapy for the treatment of neovascular AMD.
INTRODUCTION
Age-related macular degeneration (AMD) accounts for 8.7% of all blindness worldwide, 1 is the leading cause of blindness in the United
States, 2 and is expected to affect approximately 200 million patients in 2020, rising to 288 million by 2040. 1 Choroidal neovascularization (CNV; abnormal blood vessel growth from the choroid into the retina), commonly termed "wet" AMD, affects 8%-15% of AMD patients and is a rapid form of AMD that progresses to blindness if left untreated. 1, 3, 4 Current therapy for neovascular AMD consists of monthly or bimonthly intravitreal administration of anti-vascular endothelial growth factor (VEGF) biological drugs, e.g., bevacizumab (Avastin), ranibizumab (Lucentis), or aflibercept (Eylea), that sequester VEGF-A extracellularly. Although this therapeutic approach improves nearterm prognosis and increases visual stability, 5 more than half of treated eyes demonstrate ongoing CNV leakage, fibrotic scarring, and/or geographic atrophy (R. Bhisitkul, 2011, UCSF Ophthalmol., conference). [7] [8] [9] [10] Moreover, a study revealed that 7-year mean visual outcomes after anti-VEGF therapy in AMD patients declined below baseline visual acuity. 11 Hence, a drug delivery strategy that avoids intravitreal injection would reduce risks of infection, bleeding, retinal detachment, leakage, scarring, pain, and possibly damage to the retinal pigment epithelium (RPE).
To address these unmet medical needs, we developed a novel intracellular approach for the management of macular degeneration, employing nanoparticle (NP) gene delivery of Flt23k (Flt23k.NP). Flt23k is a recombinant version of VEGFR-1 (Flt-1) that expresses VEGF binding domains 2 and 3 12 and is coupled to the endoplasmic reticulum (ER) retention signal sequence Lys-Asp-Glu-Leu (KDEL), 13, 14 resulting in intracellular sequestration of VEGF and autocrine loop inhibition. Sustained delivery of the Flt23k plasmid is facilitated by suspending plasmid Flt23k (pFlt23k)-loaded nanoparticles in polylactic-co-glycolic acid (PLGA). Advantages of PLGA nanoparticles include continuous gene delivery, biodegradability, avoidance of viral-induced inflammation, immunogenicity and toxicity, and ease of production. [15] [16] [17] [18] [19] [20] [21] Nanoparticles have been used to deliver drugs (e.g., oligonucleotides and budesonide) to RPE cells in vitro and in vivo in the retina, lens, vitreous, and cornea following subconjunctival injection. 22, 23 By fine-tuning PLGA composition and molecular weight, the duration of nanoparticle delivery can be adjusted according to PLGA degradation rate, which may span months to years. Finally, to specifically target the CNV lesion, nanoparticles are coated with the Arg-Gly-Asp (RGD) tripeptide. The RGD tripeptide was originally identified as the sequence within fibronectin that mediates cell attachment. Peptides containing the RGD motif bind with high affinity to avb3-and a5b1-integrins, which are selectively upregulated in both neovascular and fibrotic CNV. 18, 20, 24, 25 RGD.Flt23k nanoparticles have been reported to reduce fibrosis in several models, including laser-induced CNV in mice, rats, and monkeys and CNV induced by subretinal injection of AAV.shRNA.sFlt-1. 26 We previously demonstrated that RGD-conjugated nanoparticles could be used to deliver plasmids expressing Flt23k (RGD.Flt23k.NPs) selectively to CNV for suppression of angiogenesis and fibrosis. 26 In this study, we specifically examined the dose response, efficacy, and safety of intravenously administered RGD.Flt23k.NPs for the regression of laser-induced CNV in mice.
RESULTS

Flt23k Overexpression Reduced Endogenous VEGF-A Expression in HeLa Cells
We tested pFlt23k 17 plasmid function in HeLa cells (Figure 1 ) before constructing and loading RGD.Flt23k.NPs. Transfection efficiency of HeLa cells was determined using nucleofection with pMaxGFP (0, 0.1, 0.5, 1.0, 2.5, and 5.0 mg). GFP expression corresponded with plasmid concentration ( Figure 1A ). Western blot analysis showed a linear decrease in endogenous VEGF level with increasing Flt23k expression ( Figure 1B ).
Flt23k.NP Inhibits HAEC Proliferation
To sidestep confounding differences in cell count from different culture flasks, we measured the optical density ratio between day 3 and day 5 ( Figure 2 ). From day 3 to day 5, 200 mg Flt23k.NP significantly decreased human aortic endothelial cell (HAEC) proliferation compared to no NP and 200 mg blank nanoparticle (Blank.NP) (p = 0.00029 and 0.00031, respectively). The 200 mg Blank.NP did not show a significant difference compared with no NP (p = 0.96). The 40 mg Flt23k.NP also significantly decreased HAEC proliferation compared with 40 mg Blank.NP (p = 0.035), but not compared with no NP (p = 0.35). The 40 mg Blank.NP did not show a significant difference compared with no NP (p = 0.21). In addition, we measured cell proliferation at day 1 and day 3 using Cell Counting Kit-8, and results similar to those given earlier were obtained ( Figure S1 ). To determine the dose response and efficacy of RGD.Flt23k.NP on regression of laser-induced CNV in mice, CNV lesions in the retina were evaluated for leakage with fluorescein angiography (FA) (Figure 3A) and volume with optical coherence tomography (OCT) ( Figures 3B and 3C ). FA showed that doses of 0 to 3 mg pFlt23k loaded in RGD.Flt23k.NP did not inhibit CNV leakage at any time point. However, 10 to 60 mg doses weakly inhibited CNV leakage between 1 and 2 weeks post-treatment and significantly reduced CNV lesions between 1 and 3 weeks post-treatment. OCT analysis showed that CNV volume did not regress with doses from 0 to 3 mg pFlt23k loaded in RGD.Flt23k.NP, but it regressed with doses between 10 and 60 mg pFlt23k loaded in RGD.Flt23k.NP. The dose response and efficacy of RGD.Flt23k.NP started to plateau around 30 mg pFlt23k loaded in RGD.Flt23k.NP, with a decrease in CNV volume of 30% at 2 weeks post-treatment. ANOVA revealed no significant difference in CNV volume regression from 30 to 60 mg pFlt23k loaded in RGD.Flt23k.NP at 2 weeks post-treatment ( Figure 3B) . To assess safety and tolerability of the Flt23k nanoparticles, we performed both single and repeated intravenous (i.v.) injections (a requirement for drug safety testing for the U.S. Food and Drug Administration (FDA), investigational new drug application) at a dose of 30 mg pFlt23k per mouse. Compared to the mice in control group, there were no significant differences in body weight (p = 0.5485) ( Figure 4A ) and organ weights (p brain = 0.1900, p heart = 0.0757, p lung = 0.0638, p liver = 0.1636, p kidney = 0.5766, p spleen = 0.2447) ( Figure 5A ) of the single-dose-treated mice before and after treatment. At 1 month post-treatment, the body weights of mice from all groups increased significantly (Sidak's test: p NC = 0.0010, p RGD.Blank.NP = 0.0070, p RGD.Flt23k.NP = 0.0001), which indicated that all mice followed the normal growth curve. Similarly, no significant differences were found between repeat-dose control and treatment groups in body weight at any time point (p = 0.3595) ( Figure 4B ) or in organ weights at the 3-month endpoint (p = 0.3595) ( Figure 5B 
DISCUSSION
In this study, we evaluated the dose response and safety of a novel i.v. delivery system for Flt23k intraceptor gene therapy, using PLGA nanoparticles to inhibit VEGF signaling. We demonstrated that regression of CNV is more pronounced and leakage is reduced at higher Flt23k concentrations. In both single-dose groups (30 mg Flt23k) and repeat-dose groups (30 mg Flt23k for 3 months), no systemic or ocular toxicity was observed with RGD.Flt23k.NP administration. Similarly, no obvious hematological and inflammatory changes or decrease in visual function were detected after i.v. administration of the experimental treatment in comparison to blank nanoparticles.
In our previous study, we found that the Flt23k intraceptor inhibited hypoxia-induced VEGF expression both in vitro and in a corneal neovascularization mouse model. 17 Based on these observations, we developed the targeted RGD.Flt23k.NP delivery system, which was found to cause regression of CNV in both mouse and monkey models. 26 However, the safety of this delivery system was previously tested using only one dose of 10 mg Flt23k. To better assess the efficacy of the RGD.Flt23k.NP delivery system, we further studied its dose response using higher concentrations of Flt23k to evaluate its safety using single short exposure and repeat dose (long-term exposure).
Our results suggest that RGD.Flt23k.NP causes a significant regression in CNV volume at 2 weeks, but not 1 week, post-treatment. The reason for the delay in CNV regression could be due to the slow release of Flt23k nanoparticles at the CNV lesion. These results correlate with our previous study, which found that the Flt23k.NP stayed at the CNV lesion site for approximately 2 weeks post-treatment. 26 Furthermore, we demonstrated greater inhibition of CNV leakage and increased CNV regression at higher doses of Flt23k. Similar to the results from our previous study, the CNV volume decreased by about 22% at a dose of 10 mg Flt23k, showing crossexperiment consistency of the RGD.Flt23k.NP delivery system. The maximum efficacy dose in reducing CNV lesion size was 30 mg pFlt23k-loaded RGD.Flt23k.NP, which resulted in a 30% regression in CNV volume (Figure 3 ). Doses higher than 30 mg pFlt23k-loaded RGD.Flt23k.NP did not significantly improve this measure. We hypothesize that this efficacy plateau at 30 mg pFlt23k loaded in RGD.Flt23k.NP corresponds to a maximum pharmacokinetic binding capacity of RGD.Flt23k.NP to endogenous receptors.
To assess the safety of RGD.Flt23k.NP, we tested the maximum efficacy dose of 30 mg pFlt23k loaded in RGD.Flt23k.NP per mouse with both single and repeat doses. Based on microscopic and systemic analysis of vital organs and plasma complement C3 levels, no local or systemic inflammatory changes were detected. These results are promising for the treatment of neovascular AMD with RGD.Flt23k.NP. Current clinical trials testing alternative therapies for neovascular AMD employ viral vectors such as adeno-associated virus serotype 2 (AAV2) and adenovirus to deliver soluble Flt-1 (sFLT1) to treat CNV lesions, 27 and these clinical trials show promising results in reducing CNV lesion size. However, higher levels of inflammatory response were shown compared to standard anti-VEGF therapy, 27 possibly be due an immune response against the viral particles. 19 We demonstrated in this study that no detectable toxicity was observed in the mouse model up to 60 mg RGD.Flt23k.NP. The existing standard anti-VEGF therapy and the AAV2-sFLT01 therapy in clinical trials use intravitreal and subretinal injections, respectively, to deliver the drugs to the posterior segment of the eye. Repeated intraocular injection of these drugs increases risk of complications such as endophthalmitis, fibrosis, and retinal detachment that could compromise the visual acuity of patients. 28 However, intravenous delivery of RGD.Flt23k.NP did not show any of the previously mentioned complications. Because we delivered RGD.Flt23k.NP systemically, we examined the safety profile in vital organs (liver, brain, kidney, lungs, and adrenal glands), where nanoparticles were shown to have the highest concentration after intravenous injection. 18 We also examined the safety profile in eyes and blood and detected no systemic, ocular, or hematological toxicity due to systemic delivery of Flt23k plasmid using the nanoparticle delivery system. Various nanoparticles are being used for developing and improving treatment of AMD. Gold nanoparticle delivery was found to reduce the radiation dosage by 49% when kilovoltage radiosurgery was employed to treat wet AMD. 29 However, radiation exposure was found in ocular structures that were not the intended target of this therapy. 29 Suen and Chau 30 used folate-modified nanoparticles to deliver steroids to RPE and found that VEGF levels were downregulated for up to 3 weeks. However, steroid use increases the risk of infections, steroid-induced cataracts, and glaucoma. To circumvent some of these intrinsic nanoparticle-associated risks, we used PLGA-based nanoparticles. PLGA is an FDA-approved biodegradable polymer that is already employed for various drug applications. 31 Although the current study clearly demonstrates that intravenous delivery of PLGA-based RGD.Flt23k.NPs can effectively reduce CNV lesions, this nanoparticle delivery system can be further improved. Elsaid et al. 32 developed PLGA-based nanoparticles with chitosan, improving the delivery of intravitreal ranibizumab (Lucentis) to CNV lesions so that it was 50% better than PLGA-based nanoparticles alone. In addition, we found that RGD.Flt23k.NP efficacy plateaus at a 30 mg dose, with a maximal reduction in CNV lesion size of 30%. Therefore, improved delivery may not improve therapeutic performance in this instance. Although no detectable systemic and inflammatory changes were found at this dose, the physiology and anatomy of mice differ from those of humans. Further exploring RGD.Flt23k.NP as a viable AMD treatment option will require good laboratory practice (GLP) toxicology studies in non-human primates. If results of such studies are promising, intravenous RGD.Flt23k.NP therapy may provide a better treatment option than the standard anti-VEGF intravitreal injection therapy for treating CNV in AMD patients.
MATERIALS AND METHODS
HeLa Cells Incubated with pFlt23k
Using nucleofection (Lonza, basic endothelial cells nucleofector kit, cat. no. VAPI-1001), pMaxGFP or pFlt23k was transfected to 6 HeLa cells and then plated to 6-well plates. Detectable GFP expression 1 day later indicated successful transfection. Two days after nucleofection, pFlt23k-transfected cells were harvested with 120 mL radioimmunoprecipitation assay (RIPA) buffer. Then, 10 mg of each protein was loaded and run on a 4%-12% NuPAGE BisTris gel and transferred to the polyvinylidene fluoride (PVDF) membrane. After blocking with 5% non-fat dry milk/Tris-buffered saline with Tween 20 (TBST) (0.1% Tween 20), the membrane was stained with 1 mg/mL anti-VEGF-A antibody (Santa Cruz, sc-507) or antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (Abcam, ab9485) in 5% non-fat dry milk/TBST. After staining the membrane with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody, enhanced chemiluminescence (ECL) was applied, and the images were taken with a FOTOdyne imaging system. and 6 mg of BSA to get primary water/oil (W/O) emulsion. Next, this primary emulsion was transferred to 15 mL 2% polyvinylalcohol (PVA) solution and sonicated for 4 min at 80 A (sequential 30 s on and off pulses), and samples were stirred at room temperature for 6 hr to evaporate the DCM. NPs were separated by centrifugation at 32,000 Â g for 30 min, and supernatant was collected to determine free plasmid concentration. Furthermore, NPs were washed twice with water to remove unbound plasmid and PVA. At the end of the wash, NPs were suspended in 5 mL of water, snap frozen in liquid N2, and lyophilized. The size and zeta potential of these NPs were determined using a Malvern Nano-ZS instrument by suspending lyophilized NPs in double-distilled water. Plasmid loading in NPs was determined indirectly, whereby absorbance spectroscopy was used to determine the free plasmid concentration in the supernatant fraction. Absorbance of supernatant fractions was recorded at 260 and 320 nm, and plasmid concentration was determined using the following formula: concentration (in micrograms per milliliter) = (A260 reading À A320 reading) Â dilution factor Â 50 mg/mL. Supernatant from control NPs was used as buffer control, and supernatant from Flt23k plasmid NPs preparation was used to determine the amount of unencapsulated plasmid. Then, the difference between total Flt23k plasmid added during NPs preparation and the amount of free plasmid in supernatant fraction was used as a measure for plasmid loading in NPs. NPs were functionalized with RGD peptide using the following method: 0.1 M MES (2-[morpholino]ethanesulfonic acid); 0.5 M NaCl ([pH 6.0] activation buffer); PBS: 0.1 M sodium phosphate, 0.15 M NaCl (pH 7.3); 80.6 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) stock in activation buffer; and 201.6 mM N-hydroxysulfosuccinimide (NHS) stock in activation buffer. Nile red and plasmid-loaded PLGA NPs were dissolved in 10 mL of MES buffer, and EDC and NHS stocks (1.25 mL of each) were added to it. PLGA NPs were activated for 2 hr at room temperature. Following activation, samples were centrifuged at 30,000 Â g for 30 min, and the pellet was resuspended in 9 mL of PBS buffer and 1.0 mL of RGD peptide stock (5 mg/mL) for 3 hr at room temperature to allow peptide conjugation. Following conjugation, the reaction mixture was centrifuged at 30,000 Â g for 30 min to separate functionalized NP from free peptide. The NP pellet was subsequently washed twice with water to remove buffer and free peptide, followed by suspension in 5 mL of water, snap freezing in liquid nitrogen, and lyophilization.
Preparation of Nanoparticle Suspension for Intravenous Delivery
Properties of RGD.Flt23k.NP and RGD.Blank.NP are shown in Table S1 . RGD.Flt23k.NP and RGD blank nanoparticles without plasmid (RGD.Blank.NP) were weighed in 1.5 mL Eppendorf tubes, suspended in 1Â PBS at appropriate experimental concentrations, and vortexed for 5 min. Then, 100 mL volumes of RGD.Flt23k.NP or control nanoparticles were injected into mouse tail veins.
Animals
Male and female C57BL/6 mice (The Jackson Laboratory) between 6 and 8 weeks of age were used to minimize variability. For the efficacy experiment, seven males were included in each group. For safety experiments, ten mice, five male and five female, were included in each group.
All animal experiments were performed in accordance with the guidelines of the Association for Research in Vision & Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. Experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Utah.
Laser-Induced CNV Mouse Model
Laser-induced CNV was performed as previously described. 26 In brief, a diode laser (532 nm; OcuLight GLx, Iridex) was used. Four laser spots (spot size, 100 mm; intensity, 120 mW; duration, 100 ms) were placed around the optic disc at 3, 6, 9, and 12 o'clock. One week after laser-induced CNV, RGD.Flt23k.NPs was administered via tail vein injection. Each group had seven male C57BL/6 mice. Spectralis (Heidelberg Engineering) imaging was performed at the first week (baseline), second week (1 week post-treatment), and third week (2 weeks post-treatment) after laser to analyze the laser-induced CNV leakage using FA and change in CNV volume using OCT.
In Vivo Evaluating CNV
The in vivo imaging of the retinal fundus was done using Heidelberg retinal angiography (HRA) and OCT using the FA and infrared (IR) modes separately. By using the volume scans in the IR mode, along with cross-sectional OCT images, three-dimensional (3D) scanning laser ophthalmoscope (SLO) images of the fundus were obtained. CNV lesions in the fundus were quantified similarly to previously described techniques for calculating CNV volumes in mouse models with Seg3D software. 26 
Mouse Body and Organ Weight Assessment
For assessing dose safety, weights of all mice were recorded before i.v. administration of RGD.Flt23k.NP or RGD.Blank.NP. For single-dose mice, weights were recorded 1 month after i.v. injection. For repeatdose groups, weights were recorded each month for 3 months. Weights of brain, heart, lung, liver, kidney, and spleen were measured at sacrifice. Body and organ weights of treatment and control groups were compared for single-dose mice and separately for repeat-dose mice.
Hemoglobin Concentration
To measure and compare the hemoglobin concentration of the RGD.Flt23k.NP-treated mice and control mice, blood was collected from the hearts of both groups at sacrifice and transferred into tubes containing EDTA. Red blood cells were separated by centrifugation at 1,000 Â g for 10 min at 4 C, collected, and lysed by mixing with water at a 1:1 ratio with vortex. Samples were diluted 10Â for the Hemoglobin Colometeris Assay Kit (Cayman Chemical, No. 700540).
Plasma Complement C3 Concentration
To measure the complement C3 levels of the treated and control mice groups, blood was collected from hearts at sacrifice and transferred into tubes containing EDTA. Tubes were centrifuged at 1,000 Â g for 10 min at 4 C, and plasma was diluted to 1:50,000 in dilution buffer before assay with the Complement C3 Mouse ELISA Kit (Abcam, ab15771).
Histological Analysis
At the endpoint, organs (brain, heart, lung, liver, kidney, and spleen) and eyes were harvested, weighed, and fixed with fresh 4% PFA for 2 days, and paraffin blocks were prepared and sectioned at 5 mm thickness as previously described. 26 All slides were stained with H&E and evaluated by an experienced pathologist. Later, the H&E sections were imaged with EVOS FL Auto Imaging Systems (Thermo Fisher Scientific).
Mouse Vision and ERG Analysis
Mouse vision was tested using the OptoMotry System (Cerebral Mechanics) as previously described, 26 and ERG was performed as previously described. 33 
Statistical Analysis
Statistical analysis was performed using Prism 7 (GraphPad). Unpaired Student's t tests were used to determine the significance for optometry results. OD 600 of crystal violet (HAEC proliferation), CNV volume inhibition rate, organ weight, hemoglobin concentration, and plasma C3 concentration were analyzed by the one-way ANOVA; further multiple comparisons were corrected by Tukey's or Dunnett's tests. The significance of differences with respect to body weight and ERG amplitude were determined with two-way ANOVA, with multiple comparisons corrected by Tukey's or Sidak's tests. Retinal thickness was analyzed by the multiple t tests, adjusted by Sidak's tests. Differences were considered significant at p < 0.05. Data are presented as the mean ± SD. 
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Supplemental Methods
Mouse vision analysis
Mouse vision was tested using the OptoMotry System (Cerebral Mechanics,) as previously described (26) . Briefly, the OptoMotry System (Cerebral Mechanics, Lethbridge, AB, Canada) displays a virtual rotating cylinder of sinusoidal grating created by 4 liquid crystal displays, one on each side of the box. A mouse was placed on a pedestal inside this box with a fixed video camera looking down at it from the top. The video acquisition displayed on the monitor was used to follow and classify mouse movements (tracking vs. non-tracking). Spatial frequency of the stimulus was changed between 0.042 cycles/degree and 0.700 cycles/degree, whereas rotation speed (12 degrees/s) and contrast (100%) were kept constant. Spatial frequency of the stimulus was stepped up or down with the staircase method to find the behavioral threshold, corresponding to the visual acuity for the behavior. Tracking was defined as a smooth pursuit movement concordant with the velocity and direction of the stimulus. Trials of each direction and spatial frequency were repeated until the presence or absence of the tracking response could be established unequivocally.
HAEC incubated with RGD.Flt23k.NP
Alternatively, we plated ~1000 cells/well with 100L in 96 well plate, then measured cell proliferation with Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc. cat: CK04, Santa Clara, CA) following the manufacture's instruction.
